A new FDA exosome warning letter, issued to R3 Medical Companies on August 14, 2026, contains a finding that should concern every practitioner who buys regenerative biologics: the agency states that products marketed as exosome products were made by a process that “does not appear would isolate exosomes.” The headline violations are the familiar ones, unapproved new drugs and manufacturing failures. The quieter finding, buried in the footnotes, is about product identity, and it is the one that changes how a buyer should think about sourcing.
What the August 2026 Warning Letter Says
FDA’s Center for Biologics Evaluation and Research inspected two co-located Scottsdale, Arizona facilities, Bello Bio LLC and Regen Suppliers LLC, between November 17 and December 16, 2025. Bello contract manufactured umbilical cord derived products under the names ReBellaWJ, ReBellaXO and ReBellaXOL; Regen approved, labeled, stored and distributed those products plus an umbilical cord blood derived product, ReBellaCB. The warning letter published by FDA was addressed to the chief executive of the parent company.
The agency made three categories of finding.
Unapproved new drugs and unlicensed biologics. FDA cited marketing material from company websites and social media describing the products as treating neurologic conditions, organ failure, diabetes, cerebral palsy and joint pain. Because that marketing establishes an intent to treat disease, the products are drugs under the FD&C Act and biological products under the PHS Act, and neither has an approved biologics license application.
Failure to qualify as a 361 HCT/P. FDA found the products fail the homologous use criterion at 21 CFR 1271.10(a)(2). Umbilical cord tissue serves as a conduit in the donor, and cord blood replenishes the lymphohematopoietic system. Treating arthritis and inflammation is not that basic function, so the products fall outside the narrow tissue pathway and require premarket review.
CGMP violations. The manufacturing findings are specific and serious, and are set out below.
The Footnote That Matters Most
The identity finding does not appear in the numbered violations. It appears in footnotes 3 and 8, and it reads plainly. Regen marketed ReBellaXO and ReBellaXOL as exosome products, but FDA records that the products manufactured by Bello use the same starting material and the same manufacturing process, with the exception of an added lyophilization step for one of them, and that this process “does not appear would isolate exosomes.” Footnote 8 repeats the concern for the Bello-branded BelloXO and BelloXOL.
Read that carefully. This is not a claim that the exosomes were of poor quality, or that the dose was low, or that the product degraded in transit. It is an observation that the documented manufacturing process does not do the thing that would produce an exosome product at all. Two products with different names and different labels came off the same process.
That is a different class of problem from the one the industry usually argues about. The debate over MSC-derived exosomes tends to be about evidence: which indications have human data, which have only animal models. This finding sits underneath that debate. If a vial does not contain what the label says, the evidence question never arises, because none of the published research on characterized vesicle preparations describes what is in the vial.
The Manufacturing Findings, in Plain Terms
The CGMP observations are worth reading as a list of things a buyer can actually ask about.
| FDA finding | What it means in practice |
|---|---|
| Aseptic processes not validated (21 CFR 211.113(b)) | Products that purport to be sterile, and are injected, were made by a process never proven to keep them sterile. |
| Manufacturing process not validated for identity, strength, quality, purity (21 CFR 211.100(a)) | No documented assurance that any two lots are the same product. |
| Samples frozen and thawed before sterility testing (21 CFR 211.160(b)) | Freezing can destroy microbial content before the test runs, so contamination present earlier may not be detected. |
| Cleaning and disinfection of the biological safety cabinet not validated (21 CFR 211.42(c)(10)(v)) | The enclosure where product is exposed to the environment was not proven to be clean. |
| 24-month expiration assigned with no stability data (21 CFR 211.166(a)) | The shelf life on the label was not supported by testing. |
| Quality control unit responsibilities not in writing (21 CFR 211.22(d)) | No written procedures for approving or rejecting product, or for handling complaints. |
FDA also noted that donor eligibility documentation omitted screening qualifiers for transmissible spongiform encephalopathy, and that responses to the Form FDA-483 observations did not address inventory already distributed and still within expiry. One further detail gives the letter its weight: FDA states it notified the same individual of substantially the same legal problem in a letter dated May 28, 2019.
Why This Is a Sourcing Story, Not Just a Compliance Story
Most coverage of regenerative enforcement focuses on the clinics that administer the product. This letter is aimed at the manufacturer and the private-label distributor, and the products moved through a partner program to affiliated clinics and to other healthcare professionals. Practitioners downstream of that chain were buying in good faith from a supplier with a professional-looking label.
There is no reliable way for a clinician to detect a product-identity problem at the bedside. A lyophilized vial looks like a lyophilized vial. The only practical defense is documentation, which is why a batch-specific certificate of analysis is not a marketing nicety. It is the single artifact connecting what is in the vial to what is on the label.
Before buying any exosome product, a practitioner should be able to see, for the specific lot being shipped:
- Particle concentration by a named method, with the instrument and dilution stated, not a round marketing number.
- Particle size distribution, confirming the population sits in the expected extracellular vesicle range rather than being dominated by debris or aggregates.
- Exosome identity markers such as CD9, CD63 and CD81, which is precisely the evidence that distinguishes an isolated exosome preparation from unprocessed conditioned material.
- Sterility and endotoxin results, with methods and limits stated, and with sample handling described.
- Stability data supporting the stated expiration date, plus documented cold chain handling.
Our manufacturing and quality standards page sets out the testing applied to every batch, and a sample certificate of analysis shows what those numbers look like in practice. If a supplier cannot produce that document for the specific lot in hand, the published literature on characterized preparations does not describe what they are selling.
Know What Is in the Vial
OmniGenix supplies characterized, batch-tested MSC-derived exosome products to licensed practitioners, with a full certificate of analysis and documented cold chain handling on every lot.
What This Does and Does Not Tell Us
A warning letter is an allegation of violations, not a final agency determination and not a court finding. The recipient has fifteen working days to respond, and FDA notes that the letter is not an all-inclusive list of deficiencies. Nothing in it establishes that any patient was harmed.
It also says nothing about whether exosome therapy works. That question is separate, and the honest answer remains what it was: no exosome product is approved by the FDA for any indication, the supporting evidence across most musculoskeletal and aesthetic applications is preclinical, and human trial data is thin. Our research library tracks that literature as it develops, and the same standards apply to stem cell products, which featured in this letter alongside the exosome products.
What the letter does establish is narrower and more actionable. In at least one documented case, a product sold to clinics as exosomes was made by a process that FDA says does not appear to isolate exosomes. That is a reason to treat certificates of analysis as a purchasing requirement rather than a formality.
Frequently Asked Questions
What did the FDA exosome warning letter actually find?
FDA found that products marketed as exosome and stem cell products were unapproved new drugs and unlicensed biologics, that they failed the homologous use criterion required to be regulated as tissue products, and that they were manufactured in violation of current good manufacturing practice. In footnotes, FDA also recorded that the manufacturing process used for the products marketed as exosomes does not appear would isolate exosomes.
Does this mean the products contained no exosomes?
FDA did not state that. The agency observed that the documented manufacturing process does not appear to isolate exosomes, and that the products marketed under different exosome names came from the same starting material and process. That is a finding about the process and about product identity, not a published assay result on vial contents.
Is any exosome product FDA approved?
No. No exosome product is approved by the FDA for the treatment of any condition. Exosome products are not licensed biologics and are not cleared devices, and any provider or supplier describing them as approved is either misinformed or misrepresenting them.
How can a practitioner tell whether a product is genuinely an isolated exosome preparation?
Not by inspection. The practical check is documentation: a batch-specific certificate of analysis showing particle concentration and size distribution by a named method, exosome identity markers such as CD9, CD63 and CD81, sterility and endotoxin results with methods stated, stability data supporting the expiration date, and documented cold chain handling. Identity markers are the specific element that speaks to whether vesicles were actually isolated.
What happens next in a case like this?
The recipient has fifteen working days to respond in writing describing corrective actions. FDA states that failure to adequately address the matters may result in further action without notice, including seizure or injunction. A warning letter is an allegation and an opportunity to respond, not a final determination.
Medical and regulatory disclaimer. This article is educational content intended for licensed healthcare practitioners and for general information. It is not medical advice, not legal advice, and does not establish a treatment protocol. Descriptions of the FDA warning letter discussed here are drawn from the published letter, which sets out alleged violations and is not a final agency determination or a judicial finding. No exosome, stem cell or peptide product described here is approved by the U.S. Food and Drug Administration for the treatment of any condition, and no outcome is promised or implied. Treatment decisions should be made by a qualified clinician with the individual patient, and all products should be used in accordance with applicable federal and state regulations.